Pharmacological characterization of novel α-calcitonin gene-related peptide (CGRP) receptor peptide antagonists that are selective for human CGRP receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 2, 2006, Pages 749-757

  Taylor, Christopher K ^a   Smith, D David ^a   Hulce, Martin ^b   Abel, Peter W ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CALCITONIN GENE RELATED PEPTIDE; ALPHA CALCITONIN GENE RELATED PEPTIDE RECEPTOR PEPTIDE ANTAGONIST; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN GENE RELATED PEPTIDE[8-37]; CYCLIC AMP; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; MALE; MIGRAINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; AORTA; CALCITONIN GENE-RELATED PEPTIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROPHOBICITY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; RECEPTORS, CALCITONIN; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33751165490     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.108316     Document Type: Article

References (22)

1. 2+ signaling pathways. Mol Cell Biochem 197:179-185.
2. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
3. Chan S and Fiscus R (2001) Vasorelaxant response to isoprenaline, nitric oxide donor, calcitonin gene-related peptide and vasoactive intestinal peptide in aortic rings of adult C57BL/6J mice. Eur J Pharmacol 431:229-236.
4. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, and Eberlein W (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129:420-423.
5. Drapeau G, Audet R, Levesque L, Godin D, and Marceau F (1993) Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins. J Pharmacol Exp Ther 266:192-199.
6. Fraser NJ, Wise A, Brown J, McLatchie LM, Main MJ, and Foord SM (1999) The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol 55:1054-1059.
7. Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, and Bairoch A (2003) ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 31:3784-3788.
8. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, and Bairoch A (2005) Protein identification and analysis tools on the ExPASy server, in The Proteomics Protocols Handbook (Walker JM ed) pp 571-607, Humana Press, Totowa, NJ.
9. Hasbak P, Saetrum Opgaard O, Eskesen K, Schifter S, Arendrup H, Longmore J, and Edvinsson L (2003) Investigation of CGRP receptors and peptide pharmacology in human coronary arteries: characterization with a nonpeptide antagonist. J Pharmacol Exp Ther 304:326-333.
10. Hilairet S, Foord SM, Marshall FH, and Bouvier M (2001) Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor- like receptor and the receptor activity-modifying proteins. J Biol Chem 276:29575-29581.
11. Husmann K, Sexton PM, Fischer JA, and Born W (2000) Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, expression and function. Mol Cell Endocrinol 162:35-43.
12. Koller D, Born W, Leuthauser K, Fluhmann B, McKinney RA, Fischer JA, and Muff R (2002) The extreme N-terminus of the calcitonin-like receptor contributes to the selective interaction with adrenomedullin or calcitonin gene-related peptide. FEBS Lett 531:464-468.
13. Kyte J and Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105-132.
14. Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS, and Kane SA (2002) Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 277:14294-14298.
15. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, and Foord SM (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature (Lond) 393:333-339.
16. Miyauchi K, Tadotsu N, Hayashi T, Ono Y, Tokoyoda K, Tsujikawa K, and Yamamoto H (2002) Molecular cloning and characterization of mouse calcitonin gene-related peptide receptor. Neuropeptides 36:22-33.
17. Pomerleau F, Fournier A, and Cadieux A (1997) Mouse aorta: a preparation highly sensitive to the vasodilatory action of CGRP. J Cardiovasc Pharmacol 30:343-351.
18. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, and Foord SM (2002) International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54:233-246.
19. Schnolzer M, Alewood P, Jones A, Alewood D, and Kent SB (1992) In situ neutralization in Boc-chemistry solid phase peptide synthesis: rapid, high yield assembly of difficult sequences. Int J Pept Protein Res 40:180-193.
20. Smith DD, Saha S, Fang G, Schaffert C, Waugh DJ, Zeng W, Toth G, Hulce M, and Abel PW (2003) Modifications to the N-terminus but not the C-terminus of calcitonin gene-related peptide(8-37) produce antagonists with increased affinity. J Med Chem 46:2427-2435.
21. Taylor CK, Abel PW, Hulce M, and Smith DD (2005) Solvent effects on coupling yields during rapid solid-phase synthesis of CGRP(8-37) employing in situ neutralization. J Pept Res 65:84-89.
22. Wisskirchen FM, Gray DW, and Marshall I (1999) Receptors mediating CGRP-induced relaxation in the rat isolated thoracic aorta and porcine isolated coronary artery differentiated by hα CGRP(8-37). Br J Pharmacol 128:283-292.